Genetic Signatures Ltd (ASX: GSS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Genetic Signatures Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $141.76 million
P/E Ratio 38.91
Dividend Yield 0.00%
Shares Outstanding 186.52 million
Earnings per share -0.124
Dividend per share N/A
Year To Date Return 72.41%
Earnings Yield 2.57%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Genetic Signatures Ltd (ASX: GSS)
    Latest News

    A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
    Small Cap Shares

    These small cap ASX shares can rise 30% to 80%: Bell Potter

    Its analysts see huge upside potential for these small caps from current levels.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    2 ASX biotech shares Bell Potter just upgraded to buy

    These biotech shares could be high risk/high reward options.

    Read more »

    Concept image of a businessman riding a bull on an upwards arrow.
    Share Gainers

    Why AGL, Genetic Signatures, Liontown, and Novonix shares are charging higher

    These ASX shares are on form on Monday...

    Read more »

    An elderly man wearing a face mask gives an excited double thumbs up.
    Healthcare Shares

    Genetic Signatures (ASX:GSS) share price leaps 6% on COVID test news

    A saliva-based test for detecting the Omicron COVID-19 variant is sending GSS shares soaring today.

    Read more »

    Female scientist in lab examines coronavirus vaccine
    Share Gainers

    20% in a week: Here's why the Genetic Signatures (ASX:GSS) share price soared today

    Investors are rewarding the molecular diagnostics company following its update.

    Read more »

    covid asx share price represented by man in face mask giving thumbs up
    Share Gainers

    Why the Genetic Signatures (ASX:GSS) share price surged 10% higher today

    The Genetic Signatures Ltd (ASX:GSS) share price was on form on Monday and surged 10% higher. Here's why investors were…

    Read more »

    Doctors and medical specialists look at the results of a drug trial, as the race for a coronavirus vaccine continues
    Share Market News

    Why the Genetic Signatures (ASX:GSS) share price is edging higher

    The Genetic Signatures Ltd (ASX: GSS) share price is edging higher today after receiving CE-IVD registration for its STI test…

    Read more »

    pair of gloved hands holding cotton swab and test tube towards car window representing Anteotech share price
    Share Gainers

    Why the Genetic Signatures (ASX:GSS) share price surged 6% higher today

    The Genetic Signatures Ltd (ASX:GSS) share price is surging higher on Thursday after revealing stellar sales growth during the first…

    Read more »

    Rocket launching into space
    Share Gainers

    Why the Genetic Signatures (ASX:GSS) share price is rocketing 25% higher

    The Genetic Signatures Ltd (ASX:GSS) share price is rocketing 25% higher on Wednesday. Here's why its shares are on fire...

    Read more »

    Share Gainers

    Why the Genetic Signatures (ASX:GSS) share price is surging 5% higher today

    The Genetic Signatures Ltd (ASX:GSS) share price has been a strong performer on Thursday. Here's why it is surging higher...

    Read more »

    Share Gainers

    Why Afterpay, Genetic Signatures, Qube, & Serko shares are charging higher

    Afterpay Ltd (ASX:APT) and Serko Ltd (ASX:SKO) shares are two of four surging higher on Friday. Here's what you need…

    Read more »

    GSS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Genetic Signatures Ltd

    Genetic Signatures Limited is a molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™

    GSS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 May 2024 $0.76 $0.01 1.33% 107,988 $0.75 $0.76 $0.75
    17 May 2024 $0.75 $0.01 1.35% 111,740 $0.74 $0.75 $0.74
    16 May 2024 $0.74 $-0.01 -1.33% 333,440 $0.75 $0.75 $0.74
    15 May 2024 $0.75 $0.00 0.00% 67,762 $0.75 $0.75 $0.74
    14 May 2024 $0.75 $0.00 0.00% 89,700 $0.75 $0.75 $0.74
    13 May 2024 $0.75 $0.01 1.35% 104,880 $0.74 $0.75 $0.74
    10 May 2024 $0.74 $-0.01 -1.34% 247,222 $0.74 $0.74 $0.71
    09 May 2024 $0.75 $0.03 4.20% 13,320 $0.74 $0.75 $0.71
    08 May 2024 $0.72 $-0.01 -1.39% 101,771 $0.72 $0.72 $0.70
    07 May 2024 $0.72 $-0.03 -4.00% 86,509 $0.75 $0.75 $0.69
    06 May 2024 $0.75 $0.05 7.09% 153,317 $0.72 $0.75 $0.71
    03 May 2024 $0.71 $0.00 0.00% 519,028 $0.70 $0.71 $0.70
    02 May 2024 $0.71 $0.01 1.43% 96,249 $0.70 $0.73 $0.68
    01 May 2024 $0.70 $0.01 1.44% 23,967 $0.70 $0.70 $0.68
    30 Apr 2024 $0.70 $-0.01 -1.43% 107,446 $0.69 $0.70 $0.64
    29 Apr 2024 $0.70 $0.01 1.46% 96,719 $0.69 $0.70 $0.68
    26 Apr 2024 $0.69 $0.01 1.47% 71,242 $0.68 $0.69 $0.63
    24 Apr 2024 $0.68 $0.00 0.00% 75,859 $0.68 $0.68 $0.68
    23 Apr 2024 $0.68 $0.01 1.48% 27,791 $0.68 $0.68 $0.68
    22 Apr 2024 $0.68 $-0.01 -1.45% 114,123 $0.70 $0.72 $0.68

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    27 Feb 2024 Stephane Chatonsky Buy 112,733 $58,621
    On-market trade.
    25 Jan 2024 Anthony (Tony) Radford Issued 36,091 $13,353
    Rights issue.
    25 Jan 2024 Caroline Waldron Issued 2,512 $929
    Rights issue.
    25 Jan 2024 Nicholas Samaras Issued 94,890 $35,109
    Rights issue.
    25 Jan 2024 Nicholas Samaras Issued 209,476 $77,506
    Rights issue.
    25 Jan 2024 John Melki Issued 164,813 $60,980
    Rights issue.
    25 Jan 2024 Stephane Chatonsky Issued 48,767 $18,043
    Rights issue.
    29 Dec 2023 Caroline Waldron Issued 250,000 $108,750
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Anthony (Tony) Radford Non-Executive Director Sep 2015
    Mr Anthony Radford was a member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics. He later joined Amrad in pharmaceutical research and was Head of Development in 2000. Establishing offices and operations in the USA, Europe and Japan, Cellestis developed QuantiFERON TB Gold, the worldwide benchmark for diagnosis of tuberculosis infection. Dr. Radford was CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011.He is a Fellow of the Australian Academy of Technology and Engineering, and a recipient of their Clunies Ross Prize.He is member of Risk Committee.
    Ms Caroline Waldron Non-Executive Director May 2022
    Ms Waldron is a cross-border advisor and director with over 30 years in governance,marketing,human resources and digital transformation across a range of sectors.Her formal training is in law and she has been admitted to the Bar of England and Wales and the courts of other jurisdictions including Australia and New Zealand. She is Chair of Risk Committee.
    Dr Nicholas Samaras Non-Executive ChairmanNon-Executive Director Jan 2008
    Mr Samaras has had over 30 years' business experience in the global Life Sciences industry and is a industry expert. He has held a number of senior executive level positions in management, marketing, sales, and research and development. His roles have included appointments as Managing Director of Applied Biosystems Pty Ltd (now part of Thermo Fisher), and senior roles with Perkin Elmer and AMRAD Corporation now part of CSL. Dr. Samaras is an experienced executive, non-executive and Board Chairman, having served on the boards of several biotechnology companies.
    Mr Michael Anton Aicher Executive Director - US Operations May 2014
    Mr Aicher has over 30 years of industry experience and was CEO and founder of National Genetics Institute NGI which was acquired by Laboratory Corporation of America,Inc.LabCorp in 2000.Mr Aicher led LabCorp's Esoteric Business Units, which generated more than $1 billion in annual revenue. Prior to NGI, Mr. Aicher served in a number of executive leadership roles at Central Diagnostics Laboratory. He currently serves as a director on boards of Roswell Biotechnologies,Techcyte and CytoBay.He is certified by the University of California at Berkeley as a Global Biotechnology Executive and is a recipient of Ernst & Young's 'Entrepreneur of the Year' award for emerging technologies.Mr Aicher received a BS in Business Administration from the University of Redlands.
    Dr Neil Gunn Executive DirectorInterim CEO Apr 2024
    Mr Gunn has over 30 years' experience in medical devices and diagnostics. Most recently Dr Gunn was CEO of ID byDNA, a metagenomics company based in the US that was acquired by Illumina in 2022. Prior to this he was the President of Roche Sequencing Solutions where he oversaw all aspects of the business and managed a team of approximately 900 people. His team developed and launched more than 20 products per year. Dr Gunn was also previously Vice President of Roche's Molecular Diagnostics business and was responsible for over 120 diagnostic product launches principally into the IVD clinical market. Dr Gunn is based in San Francisco, USA.
    Mr Stephane Chatonsky Non-Executive Director Dec 2023
    Mr Chatonsky has over 25 years of international experience including leadership roles in venture capital, private equity, investment banking, strategy and strategic advisory services.
    Mr Chatonsky has held senior executive roles with global organisations such as Lazard, McKinsey & Co, Macquarie Bank and LeapFrog Investments. In addition, he has held Non-Executive Director, Chair and advisory positions for several leading pathology, healthcare and technology companies.
    Mr Karl David Pechmann Chief Financial OfficerChief Operating OfficerCompany Secretary Jun 2023
    -
    Karl David Pechmann Chief Financial OfficerChief Operating OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Asia Union Investments Pty Ltd 37,500,000 26.15%
    HSBC Custody Nominees (Australia) Limited 17,395,196 12.13%
    National Nominees Limited 9,855,824 6.87%
    Citicorp Nominees Pty Limited 8,267,504 5.76%
    UBS Nominees Pty Ltd 3,775,944 2.63%
    J P Morgan Nominees Australia Pty Limited 3,470,046 2.42%
    Capital Concerns Pty Limited <Logue Family Super Fund A/C> 3,200,000 2.23%
    BNP Paribas Noms Pty Ltd <Drp> 2,107,405 1.47%
    Braham Consolidated Pty Ltd 1,828,463 1.27%
    Buttonwood Nominees Pty Ltd 1,662,607 1.16%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 1,575,614 1.10%
    Mr John Robert Melki 1,096,000 0.76%
    Riddler Family Investments Pty Ltd 1,053,846 0.73%
    Idollink Pty Ltd <Mckeith Super Fund A/C> 1,029,890 0.72%
    Quickinvest Pty Ltd <Quickinvest Staff S/F A/C> 1,020,000 0.71%
    Eighteen Holdings Pty Ltd 976,403 0.68%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 916,659 0.64%
    Merrill Lynch (Australia) Nominees Pty Limited 883,314 0.62%
    Braham Investments Pty Ltd <Braham Staff Super Fund A/C> 871,517 0.61%
    Juleyu Pty Ltd <Phillip Isaacs S/F A/C> 863,213 0.60%

    Profile

    since

    Note